Serina Therapeutics Inc. has received a deficiency notification from the New York Stock Exchange $(NYSE)$ regarding its stockholders' equity, which fell to $1.6 million as of September 30, 2025. The company has also reported losses in three of its four most recent fiscal years, putting it below the continued listing criteria under Sections 1003(a)(i) and (ii) of the NYSE American Company Guide. Serina must submit a compliance plan by February 8, 2026, outlining actions to regain compliance by July 9, 2027. Failure to submit an acceptable plan may result in delisting proceedings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001708599-26-000003), on January 15, 2026, and is solely responsible for the information contained therein.